Hepatic tumor necrosis factor-α production and distant organ dysfunction in a murine model of obstructive jaundice

American Journal of Surgery

Volumn 171, Issue 1, 1996, Pages 202-206

  Beierle, Elizabeth A ^a   Vauthey, Jean Nicolas ^a   Moldawer, Lyle L ^a   Copeland III, Edward M ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CREATININE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BILIRUBIN BLOOD LEVEL; COMMON BILE DUCT; CONFERENCE PAPER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOTOXICITY; FEMALE; INFLAMMATION; KIDNEY INJURY; LUNG INJURY; MOUSE; MULTIPLE ORGAN FAILURE; NONHUMAN; OBSTRUCTIVE JAUNDICE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UREA NITROGEN BLOOD LEVEL;

EID: 0030048604     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(99)80100-7     Document Type: Conference Paper

References (21)

1. Dixon JM, Armstrong CP, Duffy SW, Davies GC. Factors affecting morbidity and mortality after surgery for obstructive jaundice: a review of 373 patients. Gut. 1983;24:845-852.
2. Wait RB, Kahng KU. Renal failure complicating obstructive jaundice. Am J Surg. 1989;157:256-263.
3. Dawson JL. Post-operative renal function in obstructive jaundice: effect of a mannitol diuresis. BMJ. 1965;1:82-86.
4. Holman JRJ, Rikkers LF. Biliary obstruction and host defense failure. J Surg Res. 1982;32:208-213.
5. Bayer I, Ellis H. Jaundice and wound healing: an experimental study. Br J Surg. 1976;63:392-396.
6. van der Poll T, Lowry SF. Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense. Shock. 1995;3:1-12.
7. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987;330:662-664.
8. Lesslauer W, Tabuchi H, Gentz R, et al. Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immmol. 1991;21:2883-2886.
9. Selmaj K, Papierz W, Glabinski A, Kohno T. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J Neuroimmmol. 1995;56:135-141.
10. Espat NJ, Cendan JC, Beierle EA, et al. PEG-BP-30 monotherapy attenuates the cytokine mediated inflammatory cascade in baboon E. coli septic shock. J Surg Res. 1995;59:153-158.
11. Van Zee KJ, Kohno T, Fischer E, et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A. 1992;89:4845-4849.
12. Ginsberg HS, Moldawer LL, Sehgal PB, et al. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci U S A. 1991;88:1651-1655.
13. Colletti LM, Remick DG, Burtch GD, et al. Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. J Clin Invest. 1990;85:1936-1943.
14. Bemelmans MHA, Gouma DJ, Greve JW, Buurman WA. Effect of antitumour necrosis factor treatment on circulating tumour necrosis factor levels and mortality after surgery in jaundiced mice. Br J Surg. 1993;80:1055-1058.
15. Bemelmans MHA, Gouma DJ, Greve JW, Buurman WA. Cytokines tumor necrosis factor and interleukin-6 in experimental biliary obstruction in mice. Hepatology. 1992;15:1132-1136.
16. Greve JW, Maessen JG, Tiebosch T, et al. Prevention of postoperative complications in jaundiced rats. Ann Surg. 1990;212:221-227.
17. Pinto M, Kaplun A. Immune status in mice with experimental biliary obstruction. Clin Immunol Immunopathol. 1980;16:396-405.
18. Better OS. Bile duct ligation: an experimental model of renal dysfunction secondary to liver disease. In: Epstein M, ed. The Kidney in Liver Disease. 2nd ed. New York, NY: Elsevier Science Publishing Co, Inc; 1983:295-311.
19. Eskandari MK, Bolgos G, Miller C, et al. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol. 1992;148:2724-2730.
20. Mahoney JR Jr., Beutler BA, Le Trang N, et al. Lipopolysaccharide-treated RAW 264.7 cells produce a mediator that inhibits lipoprotein lipase in 3T3-L1 cells. J Immunol. 1985;134:1673-1675.
21. Hadjiminas DJ, McMasters KM, Robertson SE, Cheadle WG. Enhanced survival from cecal ligation and puncture with pentoxifylline is associated with altered neutrophil trafficking and reduced interleukin-1ß expression but not inhibition of tumor necrosis factor synthesis. Surgery. 1994;116:348-355.